Amazing turnout at @SCAI from the @BWHIntCard crew this year! So happy to be a part of this team @RaghavG_MD @ZaidAlMarzooq @Ajar_Kochar @PinakShahMD @BrighamWomens

🎊 Big congratulations to @sammiches14, recipient of the 2025–26 #SCAIWIN CHIP Fellowship! This prestigious award supports the advancement of women in the most complex and high-stakes areas of #InterventionalCardiology. 👩‍⚕️ Learn more ➡️ https://t.co/O9CiJ7yAZw #SCAI2025

#SCAI2025 @Ajar_Kochar We presented our very own ERGO CATH study. In this pilot study we QUANTIFY the magnitude of ergonomic risks to cath lab operator. We also compared going LEADLESS vs. wearing traditional lead aprons. Results to follow soon!! @PinakShahMD

Really proud of @RaghavG_MD Greta Campbell, @PrakritiGaba @ZaidAlMarzooq and others who helped complete ERGO CATH a prospective evaluation of ergonomic strains on Cath Lab Operators Key Slides Attached @Babar_Basir @adityadoc1 @PerwaizMeraj @SCAI @DrDamluji

Looking forward to the #SCAI First Interventional Fellow Edu prgm on Wed Feb 19 630pm, Del Frisco's (250 Northern Ave, Boston MA 02210) Register: https://t.co/BUcSDWeGIF @NilayPatelMD @EricSecemskyMD @ArjunMajithiaMD @SaurabhSDani @ericalanosborn @ZaidAlMarzooq @DougDrachmanMD

Gr8 Grand Rounds @BrighamResearch talk by Dr Blankenberg on among other things AI support tools for rapid MI diagnosis. @PinakShahMD @ZaidAlMarzooq @JKhambhati @BrianBergmark @kevinjamescroce @BrighamFellows @rohan_khera @RaghavG_MD @dmahtta @MusaSharkawiMD @RWatsonMD

🗣️Are There Disparities in the Utilization of the #Impella Device in Acute Myocardial Infarction & #CS in the US?🔎 Watch the complete interview featuring @ZaidAlMarzooq @DrMauricioCohen @rwyeh @SandeepNathanMD: 📽️ https://t.co/aK5uJGQqPT ⬇️ 📚 https://t.co/Xl2JaccwAi

🔖Post-FDA clearance, Impella use is on the rise. 🔎The authors evaluated Impella use in #AMICS & found no race/SES disparities in dissemination, likely due to severity of cases, swift market adoption, & minimal usage barriers. #MCS #CS Read more: ➡️ https://t.co/Xl2JaccwAi

The Smith Center will be at #ACC24! Full line-up in the thread below. Register here to make sure you catch all the presentations: https://t.co/Ym8AzyA3sE #CardioTwitter #Cardiology @ACCinTouch @BidmcCvi @BIDMChealth @BIDMCVFellows Saturday:

🆕 The 2024 Statistical Update is available now! Heart disease remains the leading cause of death in U.S., yet fewer than half of adults surveyed knew it was their biggest health threat. Get the latest data here: https://t.co/ohfrmOdbYq

1/ Wonderful to present our #TVTRegistry analysis on HF #GDMT prior to mitral TEER at the #ESCCongress Young Investigator Awards Session in HF, simultaneously published in #EHJ: https://t.co/ABdkDlCSvv Some key take-aways / slides below 👇

Can Impella effectiveness compared with alternative Tx for AMICS be evaluated in an observational claims dbase? @SmithBIDMC & @US_FDA investigators report in https://t.co/MWLMQtddp5 @ZaidAlMarzooq

@Ajar_Kochar @EricSecemskyMD @enricoferroMD @CAUSALab #MCS #AMICS #CardiogenicShock #CriticalCareCardiology

Want to learn more about how to interpret these findings in light of current challenges with using observational studies and how we can move forward? Check out the editorial by @djc795 & @manesh_patelMDfor their take and some key lessons. https://t.co/KfP8DYrSW0 10/10

We conclude that commonly used observational data sets cannot support a causal interpretation of the estimates produced by different analyses used for the evaluation of Impella in AMICS. RCTs of MCS will allow valid comparisons and help resolve ongoing controversies. 9/10

In the instrumented difference-in-differences analysis, 🚫 the 95% CIs were too wide to make any meaningful conclusion about harm/benefit. 8/10

In the instrumental variable analysis (method 3), Impella was also a/w ⬆️ in 30-day mortality (albeit w/ a wider 95%CI). 🚫 Assumption Violation -no exchangeability (i.e., patient & institutional differences in baseline characteristics across levels of the instrument). 7/10

In the IPTW & Grace period analyses (methods 1 & 2), Impella appeared to be a/w ⬆️ in 30-day mortality. 🚫 Assumption Violation - unmeasured confounding, as patients receiving Impella had ⬆️ frequency of factors a/w severe illness (e.g. intubation, RHC, vasopressor use). 6/10

Overall, while some methods showed an a/w worse outcomes and others were too imprecise to draw conclusions, there were important assumption violations for each of the methods that limit our causal interpretability of these results. Key findings to follow (see figure). 5/10

We included 23,478 patients with AMICS undergoing PCI between 10/2015 and 12/2019. 🔴 4,063 received Impella 🔴 12,451 received intra-aortic balloon pump (IABP) 🔴 6,694 received medical therapy 4/10